- Home
- / Innovative Pharmaceutical Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Innovative Pharmaceutical Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.2
2024-10-29
Market Capitalization
$366.3 M
2024-10-29
Revenue
$2.1 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| HKD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.8M | 18.6M | 14.6M | 15.2M | 11.1M | 8.1M | 6.6M | 2.1M |
| Cost of goods sold | 13.8M | 16.8M | 11.7M | 11.5M | 8.0M | 5.3M | 4.8M | 1.9M |
| Gross profit | 2.0M | 1.8M | 2.9M | 3.9M | 3.3M | 2.8M | 1.8M | 188.0K |
| Gross profit margin, % | 12.7% | 9.8% | 19.7% | 25.9% | 29.3% | 34.5% | 27.0% | 9.0% |
| Operating expense total | 26.4M | 28.7M | 34.0M | 23.0M | 25.5M | 21.8M | 14.3M | 13.4M |
| Depreciation and amortization | 617.0K | 67.0K | 1.2M | 2.3M | 2.1M | 1.9M | 941.0K | 297.0M |
| EBITDA | (15.8M) | (13.5M) | (24.8M) | (19.1M) | (22.2M) | (19.0M) | (12.6M) | (13.3M) |
| EBITDA margin, % | -99.7% | -72.8% | -170.1% | -125.5% | -199.4% | -235.3% | -190.5% | -633.9% |
| EBIT | (21.1M) | (98.0M) | (53.3M) | (21.2M) | 226.4M | (20.7M) | 316.7M | (310.2M) |
| EBIT margin, % | -133.3% | -527.3% | -365.7% | -139.3% | 2031.2% | -256.4% | 4804.2% | -14836.9% |
| Interest income | 9.5M | 2.0M | 21.0K | 29.0K | 3.0K | |||
| Interest expense | 110.7M | 131.7M | 147.0M | 191.0M | 190.0M | 234.0M | 218.1M | 260.1M |
| Pre tax profit | (231.0M) | (260.9M) | (222.5M) | (212.2M) | 36.4M | (254.7M) | 98.7M | (570.3M) |
| Net Income | (231.0M) | (260.9M) | (222.5M) | (212.2M) | 36.4M | (254.7M) | 98.7M | (570.3M) |